Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.53
0.051.44%
At close: -
$3.52
-0.01000-0.28%
After Hours: 7:11 PM EDT
Comments
Loading...
Perspective Therapeutics Analyst Ratings and Price Targets | AMEX:CATX | Benzinga
Perspective Therapeutics Inc has a consensus price target of $11.05 based on the ratings of 13 analysts. The high is $20 issued by UBS on October 24, 2024. The low is $1.4 issued by JonesTrading on November 15, 2023. The 3 most-recent analyst ratings were released by B. Riley Securities, Wedbush, and RBC Capital on June 23, 2025, June 23, 2025, and June 3, 2025, respectively. With an average price target of $13 between B. Riley Securities, Wedbush, and RBC Capital, there's an implied 269.32% upside for Perspective Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B. Riley Securities
Wedbush
RBC Capital
Truist Securities
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Perspective Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/23/2025 | Buy Now | 240.91% | B. Riley Securities | Yuan Zhi35% | $9 → $12 | Maintains | Buy | Get Alert |
| 06/23/2025 | Buy Now | 212.5% | Wedbush | David Nierengarten60% | $11 → $11 | Reiterates | Outperform → Outperform | Get Alert |
| 06/03/2025 | Buy Now | 354.55% | RBC Capital | Leonid Timashev40% | $15 → $16 | Maintains | Outperform | Get Alert |
| 05/14/2025 | Buy Now | 127.27% | Truist Securities | Nicole Germino61% | $10 → $8 | Maintains | Buy | Get Alert |
| 04/07/2025 | Buy Now | 184.09% | Truist Securities | Nicole Germino61% | $21 → $10 | Maintains | Buy | Get Alert |
| 03/31/2025 | Buy Now | 184.09% | HC Wainwright & Co. | Robert Burns46% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2025 | Buy Now | 326.14% | RBC Capital | Gregory Renza51% | $16 → $15 | Maintains | Outperform | Get Alert |
| 03/27/2025 | Buy Now | 212.5% | Wedbush | David Nierengarten60% | $11 → $11 | Reiterates | Outperform → Outperform | Get Alert |
| 03/19/2025 | Buy Now | 184.09% | HC Wainwright & Co. | Robert Burns46% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2025 | Buy Now | 184.09% | HC Wainwright & Co. | Robert Burns46% | → $10 | Initiates | → Buy | Get Alert |
| 03/07/2025 | Buy Now | 326.14% | Scotiabank | Louise Chen56% | → $15 | Initiates | → Sector Outperform | Get Alert |
| 01/14/2025 | Buy Now | 354.55% | RBC Capital | Gregory Renza51% | $16 → $16 | Reiterates | Outperform → Outperform | Get Alert |
| 11/25/2024 | Buy Now | 354.55% | RBC Capital | Gregory Renza51% | $25 → $16 | Maintains | Outperform | Get Alert |
| 11/25/2024 | Buy Now | 70.45% | B of A Securities | Alec Stranahan32% | $24 → $6 | Downgrade | Buy → Neutral | Get Alert |
| 11/22/2024 | Buy Now | 354.55% | Oppenheimer | Jeff Jones35% | $22 → $16 | Maintains | Outperform | Get Alert |
| 10/24/2024 | Buy Now | 468.18% | Wedbush | David Nierengarten60% | $20 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 10/24/2024 | Buy Now | 468.18% | UBS | David Dai30% | → $20 | Initiates | → Buy | Get Alert |
| 10/11/2024 | Buy Now | 525% | Oppenheimer | Jeff Jones35% | $22 → $22 | Reiterates | Outperform → Outperform | Get Alert |
| 10/01/2024 | Buy Now | 610.23% | Wedbush | David Nierengarten60% | → $25 | Initiates | → Outperform | Get Alert |
| 09/25/2024 | Buy Now | 496.59% | Truist Securities | Nicole Germino61% | → $21 | Initiates | → Buy | Get Alert |
| 09/10/2024 | Buy Now | — | Cantor Fitzgerald | Louis Chen19% | — | Reiterates | → Overweight | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Louis Chen19% | — | Reiterates | → Overweight | Get Alert |
| 09/06/2024 | Buy Now | — | Cantor Fitzgerald | Louis Chen19% | — | Reiterates | → Overweight | Get Alert |
| 09/03/2024 | Buy Now | — | Cantor Fitzgerald | Louis Chen19% | — | Reiterates | → Overweight | Get Alert |
| 08/16/2024 | Buy Now | 667.05% | RBC Capital | Gregory Renza51% | $29 → $27 | Maintains | Outperform | Get Alert |
| 08/13/2024 | Buy Now | 382.95% | Oppenheimer | Jeff Jones35% | $19 → $17 | Maintains | Outperform | Get Alert |
| 07/25/2024 | Buy Now | 581.82% | B of A Securities | Alec Stranahan32% | → $24 | Initiates | → Buy | Get Alert |
| 06/25/2024 | Buy Now | — | Cantor Fitzgerald | Louis Chen19% | — | Reiterates | → Overweight | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Louis Chen19% | — | Reiterates | → Overweight | Get Alert |
| 06/18/2024 | Buy Now | — | Oppenheimer | Jeff Jones35% | — | Reiterates | Outperform → Outperform | Get Alert |
| 06/18/2024 | Buy Now | — | Cantor Fitzgerald | Louis Chen19% | — | Reiterates | → Overweight | Get Alert |
| 06/14/2024 | Buy Now | -14.77% | RBC Capital | Gregory Renza51% | $3 → $3 | Reiterates | Outperform → Outperform | Get Alert |
| 05/16/2024 | Buy Now | -37.5% | Jones Trading | Justin Walsh42% | $1.5 → $2.2 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | -14.77% | RBC Capital | Gregory Renza51% | → $3 | Initiates | → Outperform | Get Alert |
| 05/09/2024 | Buy Now | — | Cantor Fitzgerald | Louis Chen19% | — | Initiates | → Overweight | Get Alert |
| 04/09/2024 | Buy Now | -51.7% | B. Riley Securities | Yuan Zhi35% | $1.2 → $1.7 | Maintains | Buy | Get Alert |
| 04/01/2024 | Buy Now | -57.39% | Oppenheimer | Jeff Jones35% | $1.2 → $1.5 | Reiterates | Outperform → Outperform | Get Alert |
| 03/19/2024 | Buy Now | -65.91% | Oppenheimer | Jeff Jones35% | $1.2 → $1.2 | Reiterates | Outperform → Outperform | Get Alert |
| 01/26/2024 | Buy Now | -65.91% | B. Riley Securities | Yuan Zhi35% | → $1.2 | Initiates | → Buy | Get Alert |
| 11/15/2023 | Buy Now | -60.23% | JonesTrading | Justin Walsh42% | → $1.4 | Initiates | → Buy | Get Alert |
| 05/19/2023 | Buy Now | -65.91% | Oppenheimer | Jeff Jones35% | $1 → $1.2 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Perspective Therapeutics (CATX) stock?
The latest price target for Perspective Therapeutics (AMEX:CATX) was reported by B. Riley Securities on June 23, 2025. The analyst firm set a price target for $12.00 expecting CATX to rise to within 12 months (a possible 240.91% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Perspective Therapeutics (CATX)?
The latest analyst rating for Perspective Therapeutics (AMEX:CATX) was provided by B. Riley Securities, and Perspective Therapeutics maintained their buy rating.
When was the last upgrade for Perspective Therapeutics (CATX)?
There is no last upgrade for Perspective Therapeutics
When was the last downgrade for Perspective Therapeutics (CATX)?
The last downgrade for Perspective Therapeutics Inc happened on November 25, 2024 when B of A Securities changed their price target from $24 to $6 for Perspective Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Perspective Therapeutics (CATX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Perspective Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Perspective Therapeutics was filed on June 23, 2025 so you should expect the next rating to be made available sometime around June 23, 2026.
Is the Analyst Rating Perspective Therapeutics (CATX) correct?
While ratings are subjective and will change, the latest Perspective Therapeutics (CATX) rating was a maintained with a price target of $9.00 to $12.00. The current price Perspective Therapeutics (CATX) is trading at is $3.52, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
